Click2Houston46m
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
FDA approves first new type of pain medication in 25 years
The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...
Biotech Stocks Facing FDA Decision In February 2025
February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...
FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
Eagle-Tribune17h
Gameto Announces FDA IND Clearance for Fertilo, the First iPSC-Based Therapy to Enter U.S. Phase 3 Clinical Trials
Gameto, a clinical-stage biotech company developing iPSC-based therapies for women’s health, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug ...
precisionmedicineonline1d
Atalanta Therapeutics Raises $97M in Series B Financing to Advance RNAi Therapies for CNS Diseases
Atalanta aims to create disease-modifying therapies by silencing certain genes in the central nervous system, including in the brain and spinal cord.
Vyluma Announces Acceptance of Drug Application for NVK002 by China’s National Medical Products Administration (NMPA)
With its acceptance by the NMPA, NVK002 is now under regulatory review across three major global markets: the United States, the European Union, and China. This milestone reinforces Vyluma’s vision of ...
The University of Chicago Chronicle1d
Collaboration to provide up to $130 million to fuel drug discovery, development at UChicago
Launch of Hyde Park Discovery between UChicago, Deerfield Management to accelerate research into life-saving treatments ...
TMCnet2d
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™) products for cancer and autoimmune disease, today ...
Boston biotech Atalanta raises $97M to bring CNS drugs into clinic
Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.